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This issue of Advance
features several areas of
clinical research occurring
at UT Medical Center.
Clinical trials offer many
benefits to all supporters.
They offer the patient
hope through treatment
opportunities that are
not readily available by
providing the patients
access to the novel therapies and offer the
physician scientists with more treatment options
and the ability to expand their experience in
the academic research arena. Clinical trials
also offer the institution with yet another
opportunity to expand its influence and build
upon its image in geographic s an academic
institution. Finally, clinical trials offer the
potential of a revenue stream to defray the cost
of some health care services and other in- house
initiated research. Other clinical research efforts,
such as the work being done on NIH or SBIR
grants will significantly impact patient care in
the future. This issue of Advance introduces
our newly appointed Radiology Chair, Dr.
Laura Findeiss, MD., FSIR. She brings diverse
medical experience to further integrate with the
Interventional Radiology and clinical research
efforts both in the Graduate School of Medicine
and UTMC. The Department of Medicine has
several physicians working on three industry
sponsored clinical trials that are all featured
in this issue, as well as, a clinically-relevant
imaging compound that was recently presented
at the annual meeting of the Society of Nuclear
Medicine (SNM), where it received significant
media attention. Jonathan Wall, Ph.D. and
Michael Karlstad, Ph.D. have both received large
federal grants to support their current research
efforts. All of these clinical research efforts at
UTMCK truly highlight our goal to advance
research from lab to life.
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FEATURED RESEARCHER

»»»»»»
Besides certifications in Diagnostic Radiology
and Vascular and Interventional Radiology, Dr.
Findeiss is certified by the American Board of
Vascular Medicine in Endovascular Medicine
and is a Registered Physician in Vascular
Interpretation. She has been honored as a Fellow
in the Society of Interventional Radiology (FSIR),
as well as obtaining Fellow status in the American
Heart Association.
Dr. Findeiss’s personal research interests are
peripheral arterial disease/vascular disease and
in this area limb perfusion/revascularization for
critical limb ischemia. She has an interest in tissue
perfusion imaging, and in ways to non-invasively
predict response of the critically ischemic or
ulcerated limb to revascularization therapies.

My goal is to determine how we
can best support the institution
and the exciting work the
clinicians are doing here.
-Laura Findeiss, M.D.

Surgery Residency at the UT Graduate School
of Medicine. She completed her Diagnostic
Radiology Residency at Virginia Mason Medical
Center in Seattle, Washington, in 2004, followed
by a fellowship in Vascular and Interventional
Radiology at the University of Washington
Medical Center.
As chair, Dr. Findeiss said she plans to use her
diverse medical experience to further integrate
Radiology with multidisciplinary teams at The
University of Tennessee Medical Center. She said,
“My goal is to determine how we can best support
the institution and the exciting work the clinics
are doing here. Radiology is an important part of
the healing component of our mission, and we

Laura Findeiss, M.D., FSIR, a radiologist with
a diverse professional background that includes
training in surgery at the UT Graduate School
of Medicine as well as practicing emergency
medicine in rural Tennessee, has been appointed
Chair of Radiology for the UT Graduate School
of Medicine as of August 1, 2013. Dr. Findeiss is
a noted vascular and interventional radiologist,
coming from the University of California Irvine
Medical Center where she was Division Chief of
Vascular and Interventional Radiology and CoDirector of UC Irvine’s Ablative Oncology Center.
Dr. Findeiss received her medical degree from
the University of Pittsburgh School of Medicine
in 1997 followed by two years of General
2

She has experience and interest in clinical trials
related to peripheral interventions and response of
tumors to directed therapy, specifically, response
to hepatocellular carcinoma to the spectrum of
liver directed therapies available. Dr. Findeiss is
particularly interested in the role of post-therapy
tumor hypoxia in angioneogenesis and subsequent
tumor growth. In particular, looking at hypoxia
imaging agents in this regard.
As the department chair, Dr. Findeiss’s major
research goal for the Department of Radiology
is moving the Molecular Imagining and
Translational Research Program (MITRP) forward
within the department as a comprehensive
research enterprise incorporating basic science,
translational imaging research, and investigation
of clinical applications of novel radiotracers in
collaboration with our UT Centers of Excellence.
MITRP can offer an integrated platform for bench
to bedside investigations for researchers within and
external to the institution, providing support for a
broad spectrum of research endeavors. With the
internationally recognized basic science program,
advanced animal imaging facility, and best in class
clinical PET facility with near-term development
of the on-site radiopharmacy, the opportunities for
clinically relevant scientific advances
are abundant.

work with a lot of referring physicians. I hope
to use Radiology as a hub so that diverse medical
professionals work together to support
patient care.”
Dr. Findeiss lectures nationally on a range of
Vascular and Endovascular topics, image-guided
treatment of vascular anomalies, and minimally
invasive cancer interventions, including tumor
ablation. She holds national leadership roles as a
member of the Executive Council of the Society
of Interventional Radiology, the SIR Foundation
Board of Directors, and the Leadership
Committee of the American Heart Association’s
Cardiovascular Radiology and Intervention
Council.
3

Determination of
Cardiac Amyloid
Involvement
Cardiac amyloidosis is a rare, debilitating and
inevitably fatal disease with an average survival
of only 4-9 months, from diagnosis. This disease
can often manifest with symptoms similar to
other more common cardiac conditions. Early
and accurate diagnosis of this condition is key to
providing the best possible care for these patients.
Karen Wells, M.D., Alan Solomon, M.D.
and Jonathan Wall, PhD., in the Department
of Medicine, began using Florbetapir, a
commercially available and FDA-approved

imaging compound for amyloid detection in
the brains of patients with Alzheimer’s disease,
in patients with cardiac amyloidosis. This study
was designed to examine whether or not this
compound could effectively image amyloid
outside of the brain, specifically within the heart.
Initial results from this study showed promise;
however, standard clinical PET/CT imaging
techniques were unable to show a significant
difference between patients with cardiac
amyloidosis and healthy subjects. Dr. Osborne,
4

along with Alan Stuckey and Shelley Acuff,
Director of Clinical Research for the MITRP,
began working with the group on this project
in 2012 and data acquisition was moved to the
new state of the art Biograph mCT PET/CT
scanner installed at the University of Tennessee
Cancer Institute. Dr. Osborne re-examined the
image data acquired during the scans and was
able to show, with a new type of analysis, there
were substantial differences between amyloid
patients and healthy subjects. These results
indicated that using dynamic PET imaging may
make it possible to identify patients with cardiac
amyloidosis.
The problem with dynamic method of PET
imaging used to study these patients is that it
is not performed routinely in the clinic and the
scan can last more than an hour. This makes it
extremely difficult to schedule into a busy clinical
practice. Therefore, Drs. Osborne and Wells
once again reviewed the data and found that the
scan time could be reduced to only 20 minutes.
Further analysis showed that a comparison of

the heart image between 0-5 minutes with that
at 15-20 minutes could be used to differentiate
amyloid patients from the healthy test subjects.
Specifically, the ratio of the Standard Uptake
Values (SUVs) in the heart provided the
information to accurately demonstrate cardiac
amyloidosis using Florbetapir.
This study provided preliminary support
for assessing cardiac amyloidosis using a new
clinically-relevant method using an FDAapproved amyloid imaging compound that was
easily accessible to clinicians worldwide. The
method may yield a sensitive imaging test for the
detection and diagnosis of cardiac amyloidosis.
This work was presented at the annual meeting
of the Society of Nuclear Medicine (SNM) in
Vancouver where it received significant media
attention garnering an Aunt Minne press release
as well as headlining the daily SmartBrief sent to
all members of the SNM.

Why this matters:

Use of novel compounds for rapid definitive clinical
diagnosis may alter patient management and provide
patients with improved survival.

5

Vertex Pharmaceuticals
sponsors cystic
fibrosis trial

ngoing research to find a
O
treatment for cystic fibrosis may

defect in a protein that impacts
the transport of chloride, sodium
and water in all ducts of the body.
This can cause bronchiectasis
with chronic and recurrent lung
infections, often with resistant
bacteria. Patients also suffer from
malnutrition, diabetes, liver
disease, respiratory issues and
sometimes death. Most current
medications are directed to treat
symptoms of the disease, but now
there is a drug approved to treat
the root cause of the disease.

finally pay off. Bruce Ludwig,
M.D., Medical Director, Adult
Cystic Fibrosis Program and the
clinical trial team are partnering
with Vertex Pharmaceuticals, Inc.
to study the underlying mechanism
of the gene that causes cystic
fibrosis and its protein product.
Cystic Fibrosis is the most
common fatal genetic disorder of
Caucasians, affecting about 30,000
people in the US. It is a genetic

6

Ludwig and his team expect to see significantly
improved lung function in patients and
improved weight control in the short term.
He hopes the long term effects will translate to
improved survival rates, reduced infections and
hospitalizations and eventually turn cystic fibrosis
into a much more controllable disease.
“Being able to continue to participate in trials
like these give them hope for their future,” added
Ludwig. “Hope that one day there will be a cure
for the disease that challenges their daily lives.”

This trial studies the Vertex drug, Kalydeco,
combined with Lumacaftor in patients with
cystic fibrosis. The pairing should improve
transportation to the membrane and improve
lung function. If proven to work, the outcome
would benefit at least 50% of patients with cystic
fibrosis who carry two copies of the DeltaF508
mutation. The Food and Drug Administration
called the collaboration of the two drugs,
“breakthrough therapy designation,” for its effort
to speed the development of potential treatments
for life-threatening diseases or conditions.
“These patients would not be able to receive this
type of medication if it were not for this clinical
trial,” said Ludwig.

7

EMPROVE Clinical Trial:
Evaluating a Non-surgical
Treatment Approach to
Severe Emphysema
When medical therapy is no longer effective
for patients with advanced emphysema, doctors
often have to consider interventions such as lung
volume reduction surgery. This procedure removes
the most severely damaged and over-inflated areas
of the lung, allowing the healthier lung tissue to
expand. It is a major surgery and many of the
people who need it are too frail to tolerate it.
Paul Branca, M.D., James Shamiyeh, M.D.,
and Michael McCormack, M.D., are working
on the EMPROVE trial, which is testing a new,
minimally invasive way to provide lung volume
reduction for patients without undergoing
surgery. Using a bronchoscope, a small, umbrellashaped, one-way valve is placed in the airways
leading to the damaged lung. The valves allow air
and secretions to come out of the target lobe when
the patient exhales but prevent air from reentering
on inhalation. The damaged part of the lung
deflates, allowing the healthier portion to expand.
The University of Tennessee Medical Center is
one of fewer than 20 centers in the country, and
the only center in Tennessee participating in this
trial. The trial is now open and recruiting patients
with severe emphysema who have daily symptoms.
Patients must have completed pulmonary
rehabilitation and must have quit smoking for at
least four months. Participants will be randomized
to either valve treatment or to a control group.
They will be closely monitored for six months,
then at yearly intervals. To find out more,
please contact the trial coordinator,
Lauren Davis, at 865-305-7975.

IN BRIEF

»»»»»»

Development of an Atmospheric Plasma
Applicator to Treat Chronic Wounds

Research team: Alex Nelson, Eric Karlstad, Michael Karlstad, Ph.D., Emily Paulus

Five to seven million Americans are treated
annually for chronic wounds that arise from
diabetes, lower extremity arterial disease, lower
extremity venous disease and edema, pressure
ulcers, and traumatic injuries, including burns.
Michael Karlstad, Ph.D., Department of Surgery
is a principal investigator on a two-year Small
Business Innovation Research (SBIR) grant
awarded to Advanced Plasma Products, Inc.,
from the National Institute of General Medical
Sciences, which aims to develop a prototype
for treating these wounds. Karlstad’s two other
principal investigators include Kimberly KellyWintenberg, the general manager and director
of business development from Advanced Plasma
Products, Inc. (Knoxville, TN) and Garth James,
Ph.D., a professor in the University of Montana

Center for Biofilm Engineering will help in this
endeavor.
This phase II multi-principal investigator
NIH proposal will allow the investigative team
to pursue development of an atmospheric plasma
applicator to treat chronic wounds in diabetes.
Karlstad’s research team will be responsible
for experiments designed to demonstrate the
therapeutic potential of atmospheric plasma
to improve wound healing by the removal of
microorganisms from the biofilm of chronic
diabetic wounds. Karlstad’s collaborators on
the small business grant include Patricia Coan,
D.V.M., Ph.D, Jason Collier, Ph.D., and Deidra
Mountain, Ph.D. Brian Daley, M.D. and Jeffery
Hecht , M.D., from the Department of Surgery,
will serve as clinical consultants.

Why this matters:

Why this matters:

This minimally invasive technique may be able to
provide improved quality of life to people who suffer
from severe emphysema.
8

A significant number of chronic diabetic wounds
do not heal after a year of treatment with current
technologies. This application aims to develop an
Atmospheric Plasma Applicator for treatment of
chronic wounds. The research team is working to
design a commercial prototype that is capable of
inactivating microorganisms, including, biofilm to
improve wound healing without causing damage to
surrounding tissues.
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IN BRIEF »»»»»»
The Department of Medicine
participates in clinical trial

ventilated patients. The doctors
conducting this industry sponsored
trial believe the levels achieved by
inhaling the antibiotics should be able
to effectively and safely treat infections
with multi-drug resistant bacteria.
“We are fortunate not to currently
have this problem in our hospital,”
said Rajiv Dhand, M.D. “However,
in many other hospitals, physicians
are finding it increasingly difficult to
effectively treat infections caused by
such resistant organisms and alternative methods
of treatment are urgently needed.”
These physicians believe inhaling the
antibiotics, in addition to usual standard of care,
could provide an additional means of combating
such serious, and even fatal, infections.
Inhaled therapies allow several advantages for
patients. Lower doses, with higher concentrations
of the drug, will enhance antibacterial activity
against resistant pathogens. Furthermore,
patients will experience better tolerability due to
lower prescribed doses.
Another possible benefit is that if aerosolized
medication is able to be delivered to the lungs
with more efficiency than is currently possible,
then it may prove useful as adjunctive therapy for
patients in the future.
This multi-center study will prospectively
determine the role of inhaled antibiotics in
addition to usual standard of care antibiotics for
treatment of pneumonia in ventilated patients.
UTMC is one of more than 150 sites worldwide
participating in the trial.

Pneumonia is one of the most common
infections among critically ill patients in
intensive care units nationwide. A bigger concern
to physicians is that the infection is sometimes
resistant to multiple antibiotics, making it
difficult to treat.
Rajiv Dhand, M.D., Paul Branca, M.D.,
Carol Ellis, M.D., Tina Dudney, M.D., Michael
McCormack, M.D., and Department of
Medicine fellows at the University of Tennessee
Medical Center are studying ways to combat
pneumonia by using inhaled antibiotics in

Why this matters:

These patients are considered to have a very
serious condition with a fairly high mortality rate.
Therefore, we are looking for ways to reduce the
morbidity and mortality rate of these patients.
10

IN BRIEF

»»»»»»

Doctors Investigate Impact of
Testosterone Replacement Therapy
Radio and TV ads suggest that testosterone can
cure depression, improve mood and
sexual performance, even boost
energy and melt away extra
pounds. Hormone experts
say those looking for a
quick fix are turning
to Rejuvenation
Clinics (RC) to treat
hypogonadism, or low
testosterone.
While testosterone
replacement therapy
is proven to improve
sex drive, erectile
function, muscle mass
and bone density,
there is little known
about these drugs’
effect on men’s fertility.
Jared Moss, M.D.,
chief resident, Dept. of
Urology, studied the
impact of rejuvenation
hormones on sperm
count. “Rejuvenation
Clinics are becoming
more popular and men are having
children at later ages than ever
before,” said Moss. “Testosterone
reduces sperm counts and may
compromise fertility.”

The normal range of
testosterone is 300 to 1,000 ng/dL
(nanograms per deciliter) of blood.
After age 30, men typically have a
slow decline of testosterone.
Low testosterone, or Low
T, is generally indicated at a
testosterone level under 300,
paired with symptoms such as low
sex drive, excessive fatigue, depression and
weight gain.
The data from his study
also suggests that there is a link
between prostate cancer and
testosterone. “Testosterone
does not cause prostate
cancer, but it may exacerbate
it if it is already there,” said
Moss.
Findings from Dr. Moss’
study were featured in The
Washington Post. For the
full article please see http://
www.washingtonpost.com/
national/health-science/
everything-you-need-to-knowabout-low-testosteronebut-were-afraid-toask/2013/06/24/3bdeb2d6d764-11e2-a01692547bf094cc_story.html

Why this matters:

Many of the men, as well as physicians who
prescribe testosterone, are not aware that
testosterone replacement therapy impacts
fertility negatively.
11

IN BRIEF »»»»»»
Preclinical Diagnostic Imaging of Amyloid
of antibody-related light chain
proteins in organs such as the
heart, liver, kidneys and spleen,
there is no doubt that amyloid
presence in the organs is the
cause of the disease.
There is an urgent need
to image amyloid in order
to accurately diagnose and
determine the stage of the
disease and monitor the
therapies used to treat patients.
However, in the United States
there are no clinically available
methods to image amyloid in
patients, except in those with
Alzheimer’s disease. Many
patients travel to Europe for a scan, where the
technology is available. With the help of his
team, including Steven Kennel, PhD; Alan
Stuckey, BA, CNMT; Tina Richey, MS; Sallie
Macy, BA; Craig Wooliver, MLT; Emily Martin,
BS; and Angela Williams, MS, Dr. Wall has
developed a series of new imaging agents aimed
at advancing the diagnosis and treatment of
patients with amyloid-related diseases. Dr. Wall’s
new imaging agent is a peptide, a protein he has
named p5. In preclinical testing, radioactive p5
has been shown to bind to amyloid in the brain
and other organs, making the amyloid visible
through positron emission tomography (PET)
imaging and other techniques. It is expected
that with appropriate modifications, p5 may
eventually be used in the clinical setting to image
amyloid throughout the body.

Jonathan Wall, Ph.D., professor in the
Department of Medicine and director of the
Preclinical and Diagnostic Molecular Imaging
Laboratory, received a four-year grant from
the National Institute of Diabetes and
Digestive and Kidney Diseases, a subsidiary
of the National Institutes of Health to study
“Preclinical Diagnostic Imaging of Amyloid.”
It is well known that patients with Alzheimer’s
and other disorders, such as type 2 diabetes,
develop amyloid, a substance composed of sticky
protein fibers and sugar molecules that builds
up in the brain or other organs in the body.
Doctors do not know whether this material
causes the diseases, or whether the diseases lead
to amyloid formation. However, in less common
diseases, such as light chain amyloidosis, a rare
but devastating illness caused by the aggregation

Why this matters:

In the U.S., our ability to detect amyloid deposits
is limited,” Dr. Wall said. “We’ve made amazing
progress, but we need to move faster. The peptide
p5 is the next generation of amyloid-imaging
agents, and it holds much promise for helping
people with amyloid-related diseases”.
12

News»

Alan Solomon, M.D., retires

Alan Solomon, M.D.
retired from the
University of Tennessee
after 47 years. During
his tenure at UT,
Dr. Solomon served
as a Professor in the
Department of Medicine
and as the Director of
the Human Immunology
and Cancer Research
Program. He held
National Institutes of Health grants for four
decades and maintained a very successful clinical
practice. He has given most of his adult years as a
physician and medical researcher to improve the
quality of life of his patients.

Reni Leslie, IRB Associate
Director, retires
After 32 years
of service to the
University of
Tennessee, Reni Leslie
retired at the end of
2013. For 18 of those
32 years, Reni served
the Graduate School of
Medicine as Assistant
Director of the Internal
Review Board.

Gawrysiak’s dissertation published
Former Cole Neuroscience Center PhD student,
Michael Gawrysiak, had his dissertation, titled
“Pragmatic Psychodynamic Psychotherapy for
a Patient with Depression and Breast Cancer:
Functional MRI Evaluation of Treatment
Effects”, published in the American Journal of
Psychotherapy.

UTMC appoints Clinical
Trial Director
University of Tennessee Medical Center
appointed Paul Ottaviano as the Clinical
Trial Director. Mr. Ottaviano has over 35
years of executive leadership, entrepreneurial,
research, and teaching experience in the
healthcare industry. In addition he has taught
undergraduate and graduate college level courses
from time to time as an adjunct professor, served
on the boards of colleges, presidential advisory
committees, and lead efforts to commercialize
intellectual property at Emory School of
Medicine. He will be joined by Janet Parkey,
CPA and several current site coordinators and
regulatory document staff in various clinical
departments at the University of Tennessee
Medical Center (UTMC). Together they will
develop the operation and attract sponsors of
drugs, biologics, and devices to work with the
newly created division and its physician and
medical staff supporters at UTMC.

Roger Carroll, Ph.D., retires
Roger Carroll, Ph.D. has
retired after 29 years of
service to the University
of Tennessee. Dr.
Carroll’s research efforts
predominately focused
on the area of perioperative coagulation
testing and management,
with particular focus on
assessment of platelet
function in a clinically relevant manner. He was
a valued faculty member of the Department of
Anesthesia who will be greatly missed.

Your Chance to Advance
The people at the UT Graduate School of Medicine would be happy to discuss our
research programs and how your support can help advance healthcare. For information
about philanthropic giving to the UT Graduate School of Medicine Office of Research,
please contact the development office at 865-305-6611 or development@utmck.edu.
If you would like more information about any research programs described in this
issue of Advance, please contact the UT Graduate School of Medicine’s Research
Coordinator, Kristen Bass, at 865-305-9749 or visit online:
http://gsm.utmck.edu/research/main.cfm.
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